|
Mental deterioration
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Early prevention of MCI-related risk factors provides effective means to retard cognitive decline in PD patients.
|
30732989 |
2019 |
|
Mental deterioration
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Further high-quality evidence is needed in order to determine whether mind-body interventions are cost-effective for improving cognitive decline in older adults with MCI and for delaying the rapid progression from MCI to Alzheimer or other types of dementia.
|
30712518 |
2019 |
|
Mental deterioration
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We report results from a single-case study in which DFMO was administered, for the first time, in an attempt to slow progression of AD in a single woman with multi-domain, amnestic MCI who was unable to tolerate an acetylcholinesterase inhibitor.<b>Methods:</b> Patient C.S. is a 74-year old female with a 5-year history of cognitive decline who was placed on DFMO (500 mg b.i.d.) for 12 months, with amyloid PET scans (baseline and 12-months), APOE genotyping and neuropsychological exams at baseline, 3, 9, and 12 months.<b>Results:</b> C.S. suffered continued cognitive decline over 12 months, including progressive worsening of orientation, social functions and ability to engage in IADL's.
|
29559907 |
2018 |
|
Mental deterioration
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Cognitive decline (defined as the incidence of either Parkinson's disease mild cognitive impairment [PD-MCI] or dementia [PDD], diagnosed according to published criteria and blinded to genotype) was studied as the primary outcome.
|
28869277 |
2018 |
|
Mental deterioration
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
As circadian disruption is apparent in both MCI and Alzheimer's disease, and plays a key role in cognitive function, our findings further support a circadian intervention as a potential therapeutic tool for cognitive decline.
|
30320584 |
2018 |
|
Mental deterioration
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
<b>Methods:</b> We included 2,934 patients (age 67 ± 9 years; 1,391 [47%] female; MMSE 24 ± 5) from the Amsterdam Dementia Cohort (1,347 dementia due to Alzheimer's disease [AD]; 681 mild cognitive impairment [MCI]; 906 controls with subjective cognitive decline).
|
28536518 |
2017 |
|
Mental deterioration
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In a follow-up analysis using an independent data set, we demonstrate a protective effect of this variant against risk of conversion to MCI or AD (p = 0.038) and against cognitive decline in individuals who develop dementia (p = 3.41 × 10<sup>-15</sup> ).
|
29130521 |
2017 |
|
Mental deterioration
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
To verify progressive cognitive decline we have now examined sequential changes in telomere length in 10 adults with DS (N = 4 Female, N = 6 Male) developing MCI-DS.
|
28856789 |
2017 |
|
Mental deterioration
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Higher MIF CSF levels are associated with accelerated cognitive decline in MCI and mild dementia.
|
28826184 |
2017 |
|
Mental deterioration
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In an exploratory analysis, 3/83 proteins (SGOT, MCP-1, IL6r) were also found to be mildly associated with cognitive decline in MCI subjects over a 4-year period.
|
26284520 |
2015 |